Background: Recent regulatory changes in Australia have approved 3,4-methylenedioxymethamphetamine for treating post-traumatic stress disorder and psilocybin for treatment-resistant depression. However, limited data exists on Australian mental healthcare providers’ attitudes, knowledge and readiness to implement with psychedelic-assisted psychotherapy. Methods: A cross-sectional survey was...
Alzheimer's disease (AD) is the leading cause of dementia. There are limited approved medications that delay cognitive decline or lessen neuropsychiatric symptoms. Numerous clinical trials for AD using a single drug administration have failed to meet therapeutic endpoints, which is most likely due to the complexity of AD. A multimodal therapeutic intervention is more likely to improve symptoms...
NeuropsychopharmacologyJuly 15, 2025Maria Beatriz Bistue Millón, Laura Noguera, Diana Bruno et al.4 citations
This Phase I clinical trial is the first to rigorously evaluate the safety, tolerability, and pharmacokinetics of a novel sublingual formulation of 5-MeO-DMT, administered at sub-psychedelic doses to adults with moderate to high levels of anxiety and/or depression, without formal psychiatric diagnosis or ongoing treatment. Using a double-blind, placebo-controlled design, participants received a...
The mechanism of action of serotonergic psychedelics is increasingly explored worldwide due to their clinical benefits in various psychiatric conditions. Beyond the stimulation of serotonin 2 A (5-HT2A) receptors, psychedelics may desynchronize activity between brain regions, however the involvement of corresponding neurotransmission systems has been largely overlooked. Given that monoaminergic...
Mindful Sport Performance Enhancement (MSPE) is a manualized mindfulness-based intervention for performers. The availability and adaptability of MSPE make it accessible for application and research. There has been a proliferation of research examining the effects of MSPE with performers since it's development in 2009. However, there have been no attempts to synthesize the extant literature....
The growing popularity of application-based meditation has driven the development of new technological features in this field such as the use of cardiac biofeedback, aimed at helping users train their attention to interoceptive stimuli while meditating. However, despite the innovativeness of this approach, the effectiveness of cardiac biofeedback-assisted meditation in enhancing interoception...
Cannabis use represents a significant risk factor for both psychotic disorders and suicidal behaviors, with growing evidence suggesting complex interactions between these variables. This systematic review examines the relationship between cannabis use and suicide risk in first-episode psychosis (FEP) patients, and explores underlying mechanisms, moderating factors, and intervention strategies....
Innovative therapies, such as psilocybin-assisted psychotherapies, hold great promises for treating anxiety, depression, and various other mental health disorders, addressing some of the challenges faced by conventional psychiatric medicine. This study focuses on developing and validating an HPLC-DAD methodology for detecting psilocybin and psilocin in extracts from psychedelic mushrooms...
N,N-dimethyltryptamine (DMT) is a psychedelic compound commonly co-administered with the monoamine oxidase inhibitor harmine in ayahuasca-inspired formulations. However, the impact of harmine on DMT pharmacokinetics (PK) and pharmacodynamics (PD) remains insufficiently characterized. In this single-blind, randomized, two-arm, factorial, dose-finding study, 16 healthy participants (9 males, 7...
Research into psychedelics has gained renewed interest due to their potential to address psychiatric, neurological, and other peripheral conditions. These substances offer long-term therapeutic benefits, contrasting with the side effects and limitations of current psychiatric medicines. This study examines the legislations and regulatory frameworks for psychedelics in Australia, Canada, The...